Keiichi Kuwano Selected Research

Epoprostenol (Prostacyclin)

1/2021	[Pharmacological characteristics and clinical study results of Selexipag (Uptravi® tablets), a selective prostacyclin receptor agonist].
9/2015	Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Keiichi Kuwano Research Topics

Disease

6	Pulmonary Arterial Hypertension 01/2021 - 09/2007
2	Pulmonary Hypertension 04/2023 - 09/2008
2	Right Ventricular Hypertrophy 01/2021 - 09/2008
2	Hypoxia (Hypoxemia) 01/2021 - 01/2020
2	Hypertrophy 01/2020 - 09/2008
2	Vascular Diseases (Vascular Disease) 11/2007 - 09/2007
1	Cardiovascular Diseases (Cardiovascular Disease) 09/2015
1	Arteriosclerosis Obliterans 09/2007

Drug/Important Bio-Agent (IBA)

7	selexipagIBA 04/2023 - 09/2007
6	Epoprostenol ReceptorsIBA 01/2021 - 11/2007
2	Semaxinib (SU5416)IBA 01/2021 - 01/2020
2	Epoprostenol (Prostacyclin)FDA LinkGeneric 01/2021 - 09/2015
2	acetamideIBA 01/2017 - 09/2008
1	(4- ((5,6- diphenylpyrazin- 2- yl)(isopropyl)amino)butoxy)acetic acidIBA 04/2023
1	TabletsIBA 01/2021
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2020
1	ProstaglandinsIBA 01/2017
1	MonocrotalineIBA 09/2008
1	Acetic Acid (Vinegar)FDA LinkGeneric 09/2008
1	ProdrugsIBA 09/2008

Therapy/Procedure

1	Oral Administration 01/2020